Skip to content
AnalystLens

MEDP · Medpace Holdings

131 filings

MEDP SEC Filings

Medpace Holdings - 131 total filings

Filing record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Change in control8-K · Jun ’17Jun ’17
  2. Leadership change8-K · May ’19May ’19
  3. Leadership change8-K · Jul ’21Jul ’21
  4. Material agreement8-K · Jul ’25Jul ’25
Showing 1–50 of 131 filings
10-Q

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2026

Medpace Holdings, Inc. reported third-quarter 2026 revenue, net of $716.0 million, up from $659.9 million in the prior-year quarter, and net income of $137.5 million, compared with $111.1 million. For the nine months ended September 30, 2026, revenue was $2,129.9 million versus $1,821.8 million, and net income was $382.7 million versus $316.0 million. Diluted EPS was $4.84 for the quarter and $13.37 for the nine months. The filing states that growth was primarily driven by the Metabolic, Oncology and Central Nervous System therapeutic areas. Net new business awards were $873.4 million for the quarter and $2,287.6 million for the nine months, and backlog was $3,167.2 million as of September 30, 2026. The balance sheet strengthened over the period. Cash and cash equivalents rose to $705.3 million from $497.0 million at year-end 2025, and the company had no indebtedness. Operating cash flow was $530.4 million for the nine months. Share repurchases totaled $294.7 million in the nine months, with no repurchases in the third quarter. Effective October 20, 2026, the Board terminated the existing authorization and approved a new repurchase authorization of up to $1.0 billion. The filing also discloses securities class action and derivative lawsuits filed in 2026 relating to statements about the company's book-to-bill ratio. The plaintiffs voluntarily dismissed the actions, without prejudice, in October 2026. Management stated that legal proceedings were immaterial as of September 30, 2026.

Oct 22, 2026
8-K

Medpace Holdings 8-K Report, Financial Results (Oct 21, 2026)

Medpace Holdings, Inc. reported third quarter 2026 results on October 21, 2026, as furnished under Item 2.02 with the press release attached as Exhibit 99.1. Revenue for the quarter was $716.0 million, up 8.5% from $659.9 million a year earlier, and the backlog conversion rate was 23.8%. Net new business awards were $873.4 million, up 10.6% from $789.6 million. GAAP net income was $137.5 million, or $4.84 per diluted share, versus $111.1 million, or $3.86 per diluted share, in the prior-year quarter. EBITDA was $172.1 million, up 16.0%, with an EBITDA margin of 24.0%. Backlog as of September 30, 2026 was $3,167.2 million, up 5.6%. For the nine months ended September 30, 2026, revenue was $2,129.9 million, up 16.9% on a reported basis, and GAAP net income was $382.7 million, or $13.37 per diluted share. The company forecasts 2026 revenue of $2.835 billion to $2.855 billion, GAAP net income of $514.0 million to $524.0 million, and diluted EPS of $17.97 to $18.32. Guidance excludes any share repurchases made after September 30, 2026. Under Item 8.01, the Board terminated the existing repurchase authorization, which had $527.0 million remaining and was set to expire December 31, 2026, effective October 20, 2026, and approved a new authorization of up to $1.0 billion of common stock through December 31, 2028. Repurchases are to be funded from cash on hand, and the authorization may be modified or terminated at any time. The company reported cash and cash equivalents of $705.3 million at September 30, 2026, and no share repurchases in the third quarter.

Oct 21, 2026
10-Q

Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2026

Medpace Holdings, Inc. reported a strong second quarter of 2026, with total revenue of $707.3 million for the three months ended June 30, 2026, up from $603.3 million a year earlier, and $1,413.9 million for the six months, up from $1,161.9 million. Net income was $121.4 million for the quarter versus $90.3 million, and diluted EPS was $4.25 versus $3.10. Growth was attributed primarily to the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas. Reimbursed out-of-pocket expenses, which fluctuate with program timing, rose sharply and drove much of the increase in total direct costs. Net new business awards were $795.7 million for the quarter and $1,414.2 million for the six months, and backlog stood at $3,014.2 million as of June 30, 2026. Cash and cash equivalents were $502.7 million at quarter end, and the company has no indebtedness, with a $10.0 million credit facility fully available. Operating cash flow for the first six months was $313.8 million, while the company spent $294.8 million on share repurchases during the period. Shares outstanding fell from 28,370,780 at December 31, 2025 to 27,910,605 at June 30, 2026, and shareholders' equity declined to $433.9 million from $459.1 million. Remaining repurchase authorization totaled $527.0 million. The filing also discloses two shareholder lawsuits filed in April and June 2026 relating to statements about the company's book-to-bill ratio. The company has not recognized a liability for either matter, stating that any potential loss is not currently probable or reasonably estimable.

Jul 23, 2026
8-K

Medpace Holdings 8-K Report, Financial Results (Jul 22, 2026)

Medpace Holdings, Inc. reported second quarter 2026 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Revenue was $707.3 million, up 17.2% from $603.3 million a year earlier, and GAAP net income was $121.4 million, or $4.25 per diluted share, versus $90.3 million, or $3.10 per diluted share, in the prior-year quarter. EBITDA was $153.4 million, up 17.6%, with an EBITDA margin of 21.7%. Net new business awards were $795.7 million, up 28.2%, for a net book-to-bill ratio of 1.13x, and backlog as of June 30, 2026 rose 4.9% to $3,014.2 million. For the six months ended June 30, 2026, revenue was $1,413.9 million, up 21.7% on a reported basis, and GAAP net income was $245.2 million, or $8.53 per diluted share. The company ended the quarter with $502.7 million in cash and cash equivalents, generated $162.0 million in operating cash flow in the second quarter, and repurchased 705,616 shares for $294.7 million, leaving $527.0 million under its share repurchase program. The company forecasts full-year 2026 revenue of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion. It guides to GAAP net income of $494.0 million to $514.0 million, diluted EPS of $17.25 to $17.95, and EBITDA of $618.0 million to $642.0 million. Guidance assumes a tax rate of 19.0% to 19.5% and 28.6 million diluted weighted average shares, and excludes any share repurchases after June 30, 2026. Management will host a conference call on July 23, 2026 at 9:00 a.m. ET.

Jul 22, 2026
8-K

Medpace Holdings 8-K Report, Executive Changes (Jun 4, 2026)

Medpace Holdings, Inc. (MEDP) filed a Form 8-K under Item 5.02 reporting the appointment of Brad W. Hansman, age 43, to the position of Executive Vice President, Operations, effective June 1, 2026. In this role, Mr. Hansman will perform the functions of the Company's principal operating officer alongside Susan E. Burwig, who holds the title of Executive Vice President, Operations. Mr. Hansman has been with the Company since April 2011. He began in Finance & Accounting, held various Finance roles until July 2015, and since August 2015 has held operations leadership roles including Executive Director, Vice President, and Senior Vice President, overseeing study start-up, logistics, regulatory affairs, and medical writing. Before joining the Company, he worked as an Audit Supervisor at Joseph Decosimo & Company, LLC and as an auditor at Macy's, Inc. He holds a Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). The filing states he holds no public company directorships and has no family relationships with any director, director nominee, or executive officer. Compensation disclosed in the filing consists of an annual base salary of $492,250, eligibility for the short-term incentive plan with target cash bonus opportunities described in the Company's April 1, 2026 Proxy Statement, and eligibility for the long-term equity incentive plan at the discretion of the Compensation Committee. He also entered the Company's standard director and officer indemnification agreement.

Jun 4, 2026
8-K

Medpace Holdings 8-K Report, Bylaw Amendment (May 19, 2026)

At its 2026 Annual Meeting on May 15, 2026, Medpace Holdings, Inc. stockholders approved two amendments to the Restated Certificate of Incorporation: removing supermajority voting requirements and removing the limitation on stockholders calling special meetings. The amendments became effective upon filing with the Delaware Secretary of State on May 18, 2026, and the company filed a Restated Certificate of Incorporation integrating them the same day. The Board approved conforming changes to the bylaws, under which one or more stockholders owning at least 25% of the voting power of outstanding shares may call a special meeting. Requesting stockholders must also meet notice, information, and other requirements, including having continuously owned at least 25% of the voting power for one year. Stockholders also elected five directors to serve until the 2027 Annual Meeting: Brian T. Carley, Femida H. Gwadry-Sridhar, Robert O. Kraft, August J. Troendle, and Dani S. Zander. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the advisory vote on named executive officer compensation, with 22,656,335 votes for and 1,737,558 against. In the advisory vote on say-on-pay frequency, the largest share of votes favored one year (23,989,262), and the Board determined that future advisory votes on executive compensation will be held annually. A non-binding stockholder proposal on giving shareholders the ability to call special meetings drew 8,306,071 votes for and 16,081,493 votes against, with 34,664 abstentions. The filing reports these results without describing the proposal's outcome beyond the vote counts.

May 19, 2026
10-Q

Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2026

Medpace Holdings, Inc. reported net income of $123.9 million for the quarter ended March 31, 2026, up from $114.6 million in the prior-year quarter, with diluted EPS of $4.28 versus $3.67. Revenue, net rose $148.0 million (26.5%) to $706.6 million, driven primarily by growth in the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas. Reimbursed out-of-pocket expenses, which fluctuate with program timing, rose $109.6 million, and total direct costs increased to $510.3 million from $380.2 million. Selling, general and administrative expenses fell $10.0 million to $47.9 million, mainly due to lower stock-based compensation. The balance sheet strengthened over the quarter. Cash and cash equivalents increased to $652.7 million from $497.0 million at December 31, 2025, and the company reported no indebtedness under its $10.0 million Credit Facility. Operating cash flow was $151.8 million, and shareholders' equity rose to $598.3 million from $459.1 million. The company did not repurchase any shares in the quarter, leaving $821.7 million of remaining authorization, compared with $389.8 million of repurchases in the prior-year quarter. Net new business awards were $618.4 million, and backlog reached $2,929.2 million. A securities class action was filed on April 6, 2026, in the U.S. District Court for the Southern District of Ohio against the company and three officers, alleging materially false and misleading statements about the book-to-bill ratio. The company has recorded no liability for the matter because a loss is not currently probable or reasonably estimable.

Apr 23, 2026
8-K

Medpace Holdings 8-K Report, Financial Results (Apr 22, 2026)

Medpace Holdings, Inc. reported financial results for the three months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K filed April 22, 2026. Revenue rose 26.5% to $706.6 million from $558.6 million a year earlier. Net new business awards were $618.4 million, up 23.7% from $500.0 million, for a net book-to-bill ratio of 0.88x. Backlog as of March 31, 2026 was $2,929.2 million, up 2.9% from $2,846.0 million. GAAP net income was $123.9 million, or $4.28 per diluted share, compared with $114.6 million, or $3.67 per diluted share, in the prior-year quarter. EBITDA was $149.4 million, up 25.9%, with an EBITDA margin of 21.1%. For full-year 2026, the company forecasts revenue of $2.755 billion to $2.855 billion, GAAP net income of $487.0 million to $511.0 million, EBITDA of $605.0 million to $635.0 million, and diluted EPS of $16.68 to $17.50. The guidance assumes a 19.0% to 20.0% tax rate and 29.2 million diluted weighted average shares, and excludes any share repurchases after March 31, 2026. Cash and cash equivalents were $652.7 million at March 31, 2026, and operating cash flow for the quarter was $151.8 million. The filing also discloses that President Jesse Geiger notified the company on April 21, 2026, of his intent to resign and retire effective May 31, 2026, and that the departure is not the result of any disagreement with the company. Chief Executive Officer August Troendle will reassume the role of President until a successor is appointed.

Apr 22, 2026
10-K

Medpace Holdings Annual Report, Year Ended Dec 31, 2025

Medpace Holdings, Inc. reported record 2025 results, with net revenue of $2,530,234 thousand ($2.53 billion), up from $2,109,054 thousand in 2024, and net income of $451,123 thousand ($451.1 million), up from $404,386 thousand. Income from operations rose to $534,935 thousand from $446,870 thousand. Diluted EPS was $15.28, compared with $12.63 in 2024. Growth was led by Metabolic, Oncology and Central Nervous System activity, and reimbursed out-of-pocket expenses, which fluctuate with program timing, rose $266.8 million and drove much of the increase in total direct costs. Net new business awards were $2,646.8 million in 2025 versus $2,230.0 million in 2024, and backlog increased $125.0 million, or 4.3%, to $3,027.2 million at December 31, 2025. Approximately $1,890.0 million to $1,910.0 million of that backlog is expected to convert to net revenue in 2026. The filing notes that backlog is contractually terminable without cause and is not necessarily a meaningful predictor of future results. Capital allocation was dominated by share repurchases. The company repurchased shares for $912.9 million in 2025, ended the year with $497.0 million in cash and cash equivalents, and reported no indebtedness. Remaining repurchase authorization was $821.7 million. The filing also discloses concentration and governance considerations: the top ten customers provided approximately 35.1% of net revenue, and CEO and founder August J. Troendle controls approximately 19.0% of outstanding shares.

Feb 10, 2026
8-K

Medpace Holdings 8-K Report, Financial Results (Feb 9, 2026)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported financial results for the fourth quarter and full year ended December 31, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K dated February 9, 2026. Fourth-quarter revenue rose 32.0% to $708.5 million, net new business awards were $736.6 million (a net book-to-bill ratio of 1.04x), and GAAP net income was $135.1 million, or $4.67 per diluted share. EBITDA grew 20.0% to $160.2 million, though its margin fell to 22.6% from 24.9% in the prior-year period. For the full year, revenue increased 20.0% to $2,530.2 million, GAAP net income was $451.1 million ($15.28 per diluted share), and EBITDA was $557.7 million. The company provided 2026 guidance calling for revenue of $2.755 billion to $2.855 billion, which the filing states represents growth of 8.9% to 12.8%. GAAP net income is forecast at $487.0 million to $511.0 million, diluted EPS at $16.68 to $17.50, and EBITDA at $605.0 million to $635.0 million. The guidance assumes a tax rate of 18.5% to 19.5% and 29.2 million diluted weighted average shares, and excludes any share repurchases after December 31, 2025. Capital returns were significant in 2025: the company repurchased 2,961,924 shares for $912.9 million, with no repurchases in the fourth quarter and $821.7 million remaining under its authorization at year-end. Cash and cash equivalents were $497.0 million at December 31, 2025, and backlog rose 4.3% to $3,027.2 million. Management will discuss the results on a conference call on February 10, 2026 at 9:00 a.m. ET.

Feb 9, 2026
10-Q

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2025

Medpace Holdings, Inc. reported its third-quarter 2025 results in this Form 10-Q for the period ended September 30, 2025. Revenue, net was $659.9 million for the three months ended September 30, 2025, up from $533.3 million a year earlier, and $1.82 billion for the nine months, up from $1.57 billion. Net income was $111.1 million for the quarter (diluted EPS $3.86) and $316.0 million for the nine months (diluted EPS $10.64). Income from operations rose to $141.8 million for the quarter and $381.7 million for the nine months. Net new business awards were $789.6 million for the quarter and $1.91 billion for the nine months, and backlog stood at $3,000.6 million as of September 30, 2025. The balance sheet shows a significant shift in capital allocation. Cash and cash equivalents declined to $285.4 million from $669.4 million at December 31, 2024, primarily due to share repurchases. The company repurchased 2,961,924 shares for $912.9 million during the nine months, leaving $821.7 million of remaining authorization. Total shareholders' equity fell to $293.6 million from $825.5 million, and the accumulated deficit was $(596.2) million compared with retained earnings of $8.2 million at year-end 2024. Net cash from operating activities was $520.6 million for the nine months, and the company reported no indebtedness under its $10.0 million credit facility. The company stated that its disclosure controls and procedures were effective, and it reported no material changes to its market risk disclosures or risk factors relative to its 2024 Form 10-K. Advanced billings increased to $834.3 million, and the company disclosed approximately $3.5 billion of performance obligations remaining on active projects.

Oct 23, 2025
8-K

Medpace Holdings 8-K Report, Financial Results (Oct 22, 2025)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release on October 22, 2025 (Exhibit 99.1) reporting results for the three and nine months ended September 30, 2025. Third-quarter revenue rose 23.7% to $659.9 million from $533.3 million, and net new business awards were $789.6 million, up 47.9%, for a net book-to-bill ratio of 1.20x. GAAP net income was $111.1 million, or $3.86 per diluted share, versus $96.4 million, or $3.01 per diluted share, a year earlier. EBITDA increased 24.9% to $148.4 million, with an EBITDA margin of 22.5%. Backlog as of September 30, 2025 was $3,000.6 million, up 2.5% from $2,927.4 million. For the nine months ended September 30, 2025, revenue was $1,821.8 million, up 15.9% on a reported basis, and GAAP net income was $316.0 million, or $10.64 per diluted share. Cash and cash equivalents fell to $285.4 million at September 30, 2025, from $669.4 million at December 31, 2024. During the nine months, the company repurchased 2,961,924 shares for $912.9 million, leaving $821.7 million remaining under its share repurchase program. For full-year 2025, the company forecasts revenue of $2.480 billion to $2.530 billion, GAAP net income of $431.0 million to $439.0 million, GAAP diluted EPS of $14.60 to $14.86, and EBITDA of $545.0 million to $555.0 million. The guidance excludes any share repurchases made after September 30, 2025. The company will host a conference call on October 23, 2025 at 9:00 a.m. ET.

Oct 22, 2025
10-Q

Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2025

Medpace Holdings, Inc. reported second-quarter 2025 revenue, net of $603.3 million, up from $528.1 million in the prior-year quarter, and net income of $90.3 million versus $88.4 million. For the six months ended June 30, 2025, revenue was $1.16 billion and net income was $204.9 million. Growth was primarily driven by the Metabolic, Oncology and Central Nervous System therapeutic areas. Backlog was $2,873.6 million as of June 30, 2025, a decrease of $51.3 million, or 1.8%, from $2,924.9 million a year earlier. Net new business awards were $620.5 million for the quarter and $1,120.6 million for the six months. The balance sheet changed significantly in 2025 because of share repurchases. Cash and cash equivalents fell to $46.3 million at June 30, 2025 from $669.4 million at December 31, 2024. The company repurchased $908.4 million of stock in the first half of 2025 and had $826.3 million of remaining authorization at quarter-end. Total shareholders' equity declined to $172.4 million from $825.5 million, and the accumulated deficit reached $703.2 million. The company had no indebtedness at quarter-end. In July 2025 it amended its credit facility to reduce the borrowing limit from $600.0 million to $10.0 million. Profitability was supported by a higher effective tax rate in the quarter of 27.5%, compared with 20.0% a year earlier. Operating cash flow for the six months was $274.4 million. Direct costs and SG&A rose with the growth in service activity, and SG&A for the six months increased 22.2%. The filing also notes that the One Big Beautiful Bill Act was enacted on July 4, 2025, and that management is assessing its impact on the financial statements.

Jul 22, 2025
8-K

Medpace Holdings 8-K Report, Material Agreement (Jul 21, 2025)

Medpace Holdings, Inc. reported second-quarter 2025 revenue of $603.3 million, up 14.2% from $528.1 million a year earlier. GAAP net income was $90.3 million, or $3.10 per diluted share, compared with $88.4 million, or $2.75 per diluted share, in the prior-year quarter. Net income margin fell to 15.0% from 16.7%, while EBITDA rose 16.2% to $130.5 million, with an EBITDA margin of 21.6%. Net new business awards were $620.5 million, up 12.6%, for a net book-to-bill ratio of 1.03x. Backlog decreased 1.8% to $2,873.6 million as of June 30, 2025. The company raised its 2025 outlook in the form given: revenue of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. It also forecasts GAAP net income of $405.0 million to $428.0 million, EBITDA of $515.0 million to $545.0 million, and diluted EPS of $13.76 to $14.53. The guidance assumes a tax rate of 18.5% to 19.0% and 29.4 million diluted weighted average shares, and excludes any share repurchases after June 30, 2025. Capital allocation was heavy during the period. Medpace repurchased 1,754,264 shares in the second quarter at an average price of $295.59, for $518.5 million, and $908.4 million year to date. Cash and cash equivalents were $46.3 million at June 30, 2025, compared with $669.4 million at December 31, 2024, and $826.3 million remained under the share repurchase authorization. The filing also reports an amendment to the PNC Bank unsecured credit facility, under which the line of credit may be borrowed up to $10 million. The earnings release is furnished under Item 2.02 and is not deemed filed for Section 18 purposes.

Jul 21, 2025
8-K

Medpace Holdings 8-K Report, Executive Changes (May 16, 2025)

Medpace Holdings, Inc. held its 2025 Annual Meeting of Stockholders on May 16, 2025, where stockholders approved the 2016 Amended and Restated Incentive Award Plan (the Amended 2016 Plan). The Amended 2016 Plan did not increase the number of shares authorized for issuance under the prior 2016 Incentive Award Plan; its main change is extending the expiration date to February 6, 2035. The full plan is attached as Exhibit 10.1, and a description is referenced in the Company's Definitive Proxy Statement filed April 2, 2025. Stockholders elected August J. Troendle and Dani S. Zander as Class III Directors, each to serve until the 2026 Annual Meeting. Troendle received 21,156,998 votes for and 5,128,383 withheld, while Zander received 25,858,694 votes for and 426,687 withheld, with 1,533,208 broker non-votes for each nominee. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal 2025, with 27,200,285 votes for, 600,429 against, and 17,875 abstaining. In an advisory vote on named executive officer compensation, 24,918,234 votes were cast for, 1,340,033 against, and 27,114 abstaining. A non-binding advisory stockholder proposal regarding simple majority voting was approved with 18,210,462 votes for, 8,021,457 against, and 53,462 abstaining.

May 16, 2025
10-Q

Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2025

Medpace Holdings, Inc. reported first-quarter 2025 revenue, net of $558.6 million, up from $511.0 million in the prior-year quarter, with net income of $114.6 million compared to $102.6 million. Income from operations was $113.5 million versus $104.1 million. Diluted earnings per share were $3.67, compared with $3.20 a year earlier. Growth was primarily driven by the Metabolic, Oncology, and Central Nervous System therapeutic areas. Selling, general and administrative expenses rose to $57.9 million from $44.1 million, attributed to higher personnel costs. Net new business awards were $500.0 million versus $615.6 million, and backlog was $2,846.0 million, down 2.1% from $2,907.1 million a year earlier. Capital allocation was the dominant balance sheet event. The company repurchased 1,193,011 shares for $389.8 million during the quarter, and cash and cash equivalents fell to $441.4 million from $669.4 million at December 31, 2024. Shareholders' equity declined to $593.6 million from $825.5 million, and the accumulated deficit was $(269.7) million versus retained earnings of $8.2 million at year-end 2024. The company had no indebtedness at March 31, 2025. On April 17, 2025, the Board approved an additional $1.0 billion repurchase increase, and on April 18, 2025, the credit facility was amended to increase the line of credit to up to $600.0 million. Operating cash flow was $125.8 million, compared with $152.7 million in the prior-year quarter. The effective income tax rate was 3.0%, compared with 9.0% a year earlier, reflecting excess tax benefits from share-based compensation. Total performance obligations remaining were approximately $3.4 billion.

Apr 22, 2025
8-K

Medpace Holdings 8-K Report, Material Agreement (Apr 21, 2025)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported first-quarter 2025 results on April 21, 2025. Revenue rose 9.3% to $558.6 million from $511.0 million, and GAAP net income was $114.6 million, or $3.67 per diluted share, versus $102.6 million, or $3.20 per diluted share, a year earlier. EBITDA increased 2.6% to $118.6 million, with the EBITDA margin falling to 21.2% from 22.6%. Net new business awards declined 18.8% to $500.0 million, resulting in a net book-to-bill ratio of 0.90x, and backlog decreased 2.1% to $2,846.0 million as of March 31, 2025. The company ended the quarter with $441.4 million in cash and cash equivalents and generated $125.8 million in operating cash flow. During the quarter it repurchased 1,193,011 shares at an average price of $326.78 for a total of $389.8 million. On April 17, 2025, the Board approved a $1.0 billion increase to the stock repurchase program, and $344.8 million remained under the program as of March 31, 2025. Separately, on April 18, 2025, the company's subsidiaries entered into Amendment No. 8 to the loan documents for its unsecured credit facility with PNC Bank, National Association, which increases the line of credit to up to $600 million, adjusts the interest rate and extends the revolving credit note's expiration to April 30, 2027. For 2025, the company forecasts revenue of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. It guides to GAAP net income of $378.0 million to $402.0 million, EBITDA of $462.0 million to $492.0 million, and diluted EPS of $12.26 to $13.04. The guidance assumes a tax rate of 15.5% to 16.5%, interest income of $15.8 million and 30.8 million diluted shares, and it excludes any repurchases made after March 31, 2025.

Apr 21, 2025
8-K

Medpace Holdings 8-K Report, Material Agreement (Mar 31, 2025)

Medpace Holdings, Inc. (MEDP) disclosed in this Form 8-K filed March 31, 2025 that, on March 28, 2025, its wholly owned subsidiaries Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 7 to Loan Documents with PNC Bank, National Association, relating to the company's unsecured credit facility. The principal change in Amendment No. 7 is an extension of the expiration date of the revolving credit note to March 31, 2026. The filing describes the amendment as a material definitive agreement under Item 1.01 and attaches it as Exhibit 10.1, incorporated by reference. The filing does not include any other financial results, guidance, or operational disclosures. For investors, the filing is primarily a routine maintenance event for the company's revolving credit arrangement, keeping the unsecured facility available through March 31, 2026. The full terms of the amendment are set out in Exhibit 10.1, which the summary above does not reproduce.

Mar 31, 2025
10-K

Medpace Holdings Annual Report, Year Ended Dec 31, 2024

Medpace Holdings, Inc. (NASDAQ: MEDP) describes itself as one of the world's leading clinical contract research organizations by revenue, focused solely on outsourced Phase I-IV clinical development services for biotechnology, pharmaceutical and medical device companies. For the year ended December 31, 2024, net revenue was $2,109.1 million, up $223.2 million (11.8%) from $1,885.8 million in 2023. Income from operations rose to $446.9 million from $336.8 million, and net income increased to $404.4 million from $282.8 million, with diluted EPS of $12.63 compared with $8.88. Growth was described as broad based but primarily driven by Metabolic, Oncology, Cardiology and other uncategorized therapeutic areas. Net new business awards were $2,230.0 million in 2024 versus $2,356.7 million in 2023. Backlog rose $89.2 million, or 3.2%, to $2,902.2 million at December 31, 2024, of which approximately $1,620.0 million to $1,640.0 million is expected to convert to net revenue in 2025. Cash and cash equivalents increased to $669.4 million from $245.4 million, operating cash flow was $608.8 million, and the company had no indebtedness at year end. The company repurchased $174.2 million of stock in the fourth quarter alone for the year-ended 2024 program, and in February 2025 the Board added $600.0 million to its repurchase program. The filing highlights concentration and structural risks: the top ten customers generated approximately 28.9% of net revenue, most contracts are terminable on about 30 days' notice, and the CEO and founder, August J. Troendle, controls approximately 17.6% of outstanding shares. Deloitte & Touche LLP audited the financial statements and reported effective internal control over financial reporting as of December 31, 2024.

Feb 11, 2025
8-K

Medpace Holdings 8-K Report, Financial Results (Feb 10, 2025)

Medpace Holdings, Inc. reported fourth-quarter 2024 revenue of $536.6 million, up 7.7% from $498.4 million a year earlier, and full-year 2024 revenue of $2.109 billion, up 11.8% from $1.886 billion. GAAP net income was $117.0 million ($3.67 per diluted share) for the quarter and $404.4 million ($12.63 per diluted share) for the year. EBITDA rose 39.3% to $133.5 million in the fourth quarter, with an EBITDA margin of 24.9%, and rose 32.5% to $480.2 million for the full year, with a 22.8% margin. Backlog increased 3.2% to $2,902.2 million at December 31, 2024. New business momentum softened in the quarter. Net new business awards were $529.7 million in the fourth quarter, down 13.8% from $614.7 million a year earlier, giving a net book-to-bill ratio of 0.99x. For the full year, awards totaled $2,230.0 million, a 1.06x book-to-bill ratio, compared with $2,356.7 million in 2023. Cash and cash equivalents were $669.4 million at year-end, and the company repurchased 527,160 shares in the fourth quarter for $174.2 million. For 2025, Medpace guided to revenue of $2.110 billion to $2.210 billion, which the filing describes as growth of 0.0% to 4.8%, GAAP net income of $378.0 million to $402.0 million, EBITDA of $462.0 million to $492.0 million, and diluted EPS of $11.93 to $12.69. The guidance assumes a tax rate of 18.0% to 19.0% and 31.7 million diluted shares, and excludes any repurchases after December 31, 2024. On February 6, 2025, the Board approved a $600 million increase to the stock repurchase program.

Feb 10, 2025
10-Q

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2024

Medpace Holdings, Inc. reported strong third-quarter 2024 results in its Form 10-Q for the period ended September 30, 2024. Total revenue was $533.3 million for the three months ended September 30, 2024, up from $492.5 million a year earlier, and $1.57 billion for the nine months, up from $1.39 billion. Income from operations rose to $112.3 million for the quarter from $84.9 million, and net income was $96.4 million, or $3.01 per diluted share, compared with $70.6 million, or $2.22 per diluted share, in the prior-year quarter. The filing states that growth was driven primarily by the Metabolic, Oncology and Cardiology therapeutic areas. Backlog reached $2,927.4 million as of September 30, 2024, up from $2,689.5 million a year earlier, and net new business awards were $533.7 million for the quarter and $1,700.3 million for the nine months. The company expects roughly $1,610.0 million to $1,630.0 million of backlog to convert to net revenue over the next twelve months. Balance sheet liquidity strengthened considerably. Cash and cash equivalents were $656.9 million at September 30, 2024, up from $245.4 million at December 31, 2023, and the company reported no indebtedness. Net cash provided by operating activities was $418.1 million for the nine months, and no share repurchases were executed during 2024 through September 30, with $308.8 million remaining under the repurchase authorization.

Oct 22, 2024
8-K

Medpace Holdings 8-K Report, Financial Results (Oct 21, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported third quarter 2024 results on October 21, 2024, via a press release furnished as Exhibit 99.1 under Item 2.02. Third quarter revenue rose 8.3% to $533.3 million from $492.5 million, while net new business awards were $533.7 million, down 12.7% from $611.5 million, giving a net book-to-bill ratio of 1.00x. Backlog increased 8.8% to $2,927.4 million as of September 30, 2024. Profitability improved substantially. GAAP net income for the quarter was $96.4 million, or $3.01 per diluted share, versus $70.6 million, or $2.22 per diluted share, a year earlier. EBITDA rose 31.7% to $118.8 million, with an EBITDA margin of 22.3% compared with 18.3% in the prior-year period. For the nine months ended September 30, 2024, revenue was $1,572.5 million, up 13.3%, and GAAP net income was $287.4 million, or $8.96 per diluted share. The company ended the quarter with $656.9 million in cash and cash equivalents and generated $149.1 million in operating cash flow in the third quarter. No share repurchases were made in the quarter, and $308.8 million remained under the authorized repurchase program. Full-year 2024 guidance calls for revenue of $2.090 billion to $2.130 billion, GAAP net income of $376.0 million to $388.0 million, and EBITDA of $450.0 million to $470.0 million.

Oct 21, 2024
10-Q

Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2024

Medpace Holdings, Inc. reported strong second-quarter 2024 results in its Form 10-Q. Net revenue rose 14.6% to $528.1 million for the three months ended June 30, 2024, from $460.9 million a year earlier, and rose 16.1% to $1,039.1 million for the six months. The filing attributes the growth to Metabolic, Oncology and Other therapeutic areas. Income from operations was $105.2 million for the quarter versus $78.4 million, and net income was $88.4 million versus $61.1 million. Diluted EPS was $2.75 compared with $1.93. For the six months, net income was $190.9 million and diluted EPS was $5.96, versus $134.0 million and $4.20 in the prior-year period. Liquidity strengthened considerably. Cash and cash equivalents increased to $510.9 million from $245.4 million at December 31, 2023, and net cash provided by operating activities was $269.1 million for the six months, compared with $162.6 million. Advanced billings rose to $638.4 million from $559.9 million. The company reported no indebtedness at June 30, 2024, and its credit facility line was reduced to up to $10.0 million. Shareholders' equity increased to $763.6 million, and the accumulated deficit narrowed to $30.8 million from $221.6 million. Forward indicators were mixed. Backlog increased $353.0 million, or 13.7%, to $2,924.9 million, and the company expects approximately $1,575.0 million to $1,595.0 million of that backlog to convert to net revenue over the next twelve months. Net new business awards were $551.0 million in the quarter, compared with $574.8 million a year earlier, and $1,166.5 million for the six months, compared with $1,130.6 million. The company made no share repurchases in the first half of 2024 and had $308.8 million of remaining authorization under its repurchase program.

Jul 23, 2024
8-K

Medpace Holdings 8-K Report, Financial Results (Jul 22, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release under Item 2.02 reporting its financial results for the three and six months ended June 30, 2024. Revenue for the second quarter of 2024 was $528.1 million, up 14.6% from $460.9 million a year earlier, with a backlog conversion rate of 18.2%. Net new business awards were $551.0 million, a 4.1% decrease from $574.8 million, producing a net book-to-bill ratio of 1.04x. GAAP net income rose to $88.4 million, or $2.75 per diluted share, from $61.1 million, or $1.93 per diluted share, and EBITDA increased 34.2% to $112.3 million, a 21.3% margin. For the first half of 2024, revenue was $1,039.1 million, up 16.1%, and GAAP net income was $190.9 million, or $5.96 per diluted share. Backlog as of June 30, 2024 increased 13.7% to $2,924.9 million. Cash and cash equivalents were $510.9 million at quarter end, and the company reported no share repurchases in the second quarter, with $308.8 million remaining under its authorized repurchase program. For full-year 2024, the company forecasts revenue of $2.125 billion to $2.175 billion, GAAP net income of $361.0 million to $383.0 million, EBITDA of $430.0 million to $460.0 million, and diluted EPS of $11.24 to $11.93. The guidance assumes a tax rate of 15.0% to 16.0%, interest income of $24.0 million, and 32.1 million diluted shares, and excludes any repurchases after June 30, 2024. A conference call is scheduled for 9:00 a.m. ET on July 23, 2024.

Jul 22, 2024
8-K

Medpace Holdings 8-K Report, Executive Changes (Jul 3, 2024)

Medpace Holdings, Inc. disclosed in this Form 8-K, filed July 3, 2024 under Item 5.02, that director Ashley M. Keating resigned from the Board of Directors effective June 30, 2024. The filing states her resignation did not result from any disagreement with the Company on matters relating to its operations, policies or practices. The Board, following a recommendation from its independent directors, unanimously elected Dr. Dani S. Zander to fill the resulting Class III director vacancy, effective July 1, 2024, with her term running until the 2025 Annual Meeting of Stockholders. Dr. Zander was also appointed to the Nominating and Governance Committee effective the same date. She is the MacKenzie Chair of the Department of Pathology and Laboratory Medicine at the University of Cincinnati and Chief of Pathology and Laboratory Medicine for UC Health, and the filing describes her background in lung pathology, cytopathology and academic pathology leadership. Under the Company's standard non-employee director compensation program, Dr. Zander received on July 1, 2024 an option to purchase 824 shares of common stock at an exercise price equal to that day's closing price, with a seven-year term. The Company also entered into its standard director and officer indemnification agreement with her.

Jul 3, 2024
8-K

Medpace Holdings 8-K Report, Bylaw Amendment (May 21, 2024)

At its 2024 Annual Meeting of Stockholders, held May 17, 2024, Medpace Holdings, Inc. stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to begin phasing out the Company's classified Board of Directors. Directors up for election at and after the 2025 Annual Meeting will be elected annually. The amendment became effective upon filing with the Delaware Secretary of State on May 17, 2024, and the Company then filed a new Restated Certificate of Incorporation the same day. The Board also approved conforming amendments to the Amended and Restated Bylaws to remove the requirement that the Board be divided into three classes. Stockholders re-elected Class II directors Fred B. Davenport, Jr. and Cornelius P. McCarthy III, each to serve until the 2027 Annual Meeting. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The advisory vote on named executive officer compensation was approved, with 26,373,187 votes for and 701,630 against. The filing's other stockholder votes were also approved. The declassification amendment received 27,081,976 votes for and 4,407 against. The filing reports these results and incorporates the full amended governing documents, Exhibits 3.1 and 3.2, by reference.

May 21, 2024
10-Q

Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2024

Medpace Holdings, Inc. reported first-quarter 2024 revenue, net of $511.0 million, up from $434.1 million in the first quarter of 2023, with the filing stating the increase was broad based but primarily driven by the Metabolic, Oncology, AVAI and Other therapeutic areas. Income from operations was $104.1 million versus $86.2 million a year earlier, and net income was $102.6 million, compared with $72.9 million. Diluted EPS was $3.20 versus $2.27. The effective tax rate fell to 9.0% from 15.3%, which the company attributed mainly to excess tax benefits from share-based compensation and Foreign Derived Intangible Income benefits. Backlog rose to $2,907.1 million as of March 31, 2024, up $447.0 million, or 18.2%, from $2,460.1 million a year earlier. Net new business awards were $615.6 million for the quarter, compared with $555.8 million in the prior-year quarter. Net cash provided by operating activities was $152.7 million, helped by a $56.8 million increase in advanced billings. Cash and cash equivalents rose to $407.0 million from $245.4 million at December 31, 2023. The company made no share repurchases in the quarter, leaving $308.8 million of authorization under its $500.0 million program. It had no indebtedness at March 31, 2024. The credit facility was reduced to a $10.0 million revolving line, with $10.0 million available for borrowing. Shareholders' equity increased to $671.5 million from $558.9 million.

Apr 23, 2024
8-K

Medpace Holdings 8-K Report, Financial Results (Apr 22, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported first quarter 2024 results on April 22, 2024, as furnished under Item 2.02 of this Form 8-K (press release attached as Exhibit 99.1). Revenue rose 17.7% to $511.0 million from $434.1 million a year earlier, and backlog increased 18.2% to $2,907.1 million. Net new business awards were $615.6 million, up 10.8%, for a net book-to-bill ratio of 1.20x. Profitability improved meaningfully. GAAP net income was $102.6 million, or $3.20 per diluted share, versus $72.9 million, or $2.27 per diluted share, in the prior-year quarter, with net income margin of 20.1% compared to 16.8%. EBITDA increased 24.6% to $115.7 million, a 22.6% margin. Cash and cash equivalents were $407.0 million at March 31, 2024, and operating cash flow was $152.7 million for the quarter. No share repurchases were made in the quarter, and $308.8 million remained under the authorized repurchase program. For full-year 2024, the company forecasts revenue of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue of $1.886 billion. GAAP net income is forecast at $347.0 million to $369.0 million, diluted EPS (GAAP) at $10.79 to $11.47, and EBITDA at $415.0 million to $445.0 million. The guidance assumes a 15.0% to 16.0% tax rate and 32.1 million diluted shares outstanding, and excludes any share repurchases after March 31, 2024.

Apr 22, 2024
8-K

Medpace Holdings 8-K Report, Material Agreement (Mar 29, 2024)

Medpace Holdings, Inc. (MEDP) reported in an 8-K filed March 29, 2024 that on March 28, 2024, its wholly owned subsidiaries Medpace, Inc. (as borrower) and Medpace IntermediateCo, Inc. (as guarantor) entered into Amendment No. 6 to Loan Documents with PNC Bank, National Association, relating to the Company's unsecured credit facility. According to the filing, Amendment No. 6 changes the aggregate principal amount that may be borrowed under the facility's line of credit to up to $10 million and extends the expiration date of the revolving credit note to March 31, 2025. The filing states that the full terms are qualified by reference to the amendment, which is filed as Exhibit 10.1. The filing is a limited material-agreement disclosure under Item 1.01. It contains no financial results, operating metrics, or guidance, so the amendment's main investor-relevant points are the borrowing capacity and the extended maturity of the revolving credit note.

Mar 29, 2024
10-K

Medpace Holdings Annual Report, Year Ended Dec 31, 2023

Medpace Holdings, Inc. reported a strong 2023 in its 10-K filed February 13, 2024. Revenue, net rose $425.8 million, or 29.2%, to $1,885.8 million, up from $1,460.0 million in 2022. Income from operations reached $336.8 million, and net income was $282.8 million, compared with $245.4 million in 2022. Diluted EPS was $8.88, versus $7.28 a year earlier. Growth was broad based, driven mainly by Metabolic, Oncology, and AVAI therapeutic areas. Backlog grew $473.4 million, or 20.2%, to $2,813.0 million at December 31, 2023. Net new business awards were $2,356.7 million, up from $1,829.5 million. The company expects approximately $1,520.0 million to $1,540.0 million of backlog to convert to net revenue in 2024. The filing also notes that most customer contracts are terminable without cause on 30 days' notice, so backlog is not necessarily a meaningful predictor of future results. Cash and cash equivalents increased to $245.4 million from $28.3 million, and the company reported no outstanding indebtedness at year-end 2023. Operating cash flow was $433.4 million. The company repurchased $144.0 million of common stock during 2023 and had $308.8 million remaining under its current repurchase authorization. Risk factors highlight customer concentration (top ten customers at 29.5% of net revenue), fixed-fee contract exposure, and the influence of Chief Executive Officer and founder August J. Troendle, who controls approximately 20.8% of outstanding shares.

Feb 13, 2024
8-K

Medpace Holdings 8-K Report, Financial Results (Feb 12, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported fourth-quarter and full-year 2023 results in a press release dated February 12, 2024, furnished as Exhibit 99.1 to this Form 8-K under Item 2.02. For the fourth quarter, revenue increased 26.5% to $498.4 million, net new business awards were $614.7 million (a 1.23x net book-to-bill ratio), and GAAP net income was $78.3 million, or $2.46 per diluted share. EBITDA rose 19.2% to $95.8 million. For the full year 2023, revenue increased 29.2% to $1,885.8 million, GAAP net income was $282.8 million, or $8.88 per diluted share, and EBITDA was $362.5 million. Backlog as of December 31, 2023 increased 20.2% to $2,813.0 million. The company issued 2024 guidance calling for revenue of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue. It expects GAAP net income of $326.0 million to $348.0 million, diluted EPS of $10.18 to $10.87, and EBITDA of $400.0 million to $430.0 million. The guidance assumes a tax rate of 16.0% to 17.0%, interest income of $18.4 million, and 32.0 million diluted shares, and excludes any future share repurchases. On the balance sheet, cash and cash equivalents were $245.4 million at December 31, 2023, up from $28.3 million a year earlier, and operating cash flow for the full year was $433.4 million. The company repurchased 781,068 shares for $144.0 million in 2023 and had $308.8 million remaining under its repurchase program. The filing also notes a conference call on February 13, 2024 at 9:00 a.m. ET.

Feb 12, 2024
10-Q

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2023

Medpace Holdings, Inc. reported strong growth in its third quarter ended September 30, 2023. Total revenue, net was $492.5 million for the three months ended September 30, 2023, up from $383.7 million a year earlier, and $1,387.4 million for the nine months, up from $1,065.9 million. Income from operations rose to $84.9 million for the quarter from $77.8 million, and net income was $70.6 million, compared with $66.0 million in the prior-year quarter. Diluted EPS was $2.22 for the quarter versus $2.05, and $6.42 for the nine months versus $5.18. The filing attributes revenue growth primarily to Oncology, Metabolic, AVAI and other therapeutic areas. Backlog was $2,689.5 million as of September 30, 2023, and net new business awards were $611.5 million for the quarter and $1,742.1 million for the nine months. Balance sheet and cash flow strengthened over the period. Cash and cash equivalents rose to $95.2 million from $28.3 million at December 31, 2022, and the company reported no indebtedness as of September 30, 2023, after repaying its short-term debt. Net cash provided by operating activities was $277.0 million for the nine months, versus $251.4 million a year earlier. The company repurchased 781,068 shares for $144.0 million in the nine months ended September 30, 2023, and did not repurchase shares in the third quarter. Remaining authorization under the new $500.0 million repurchase program was $308.8 million. The company's effective tax rate was 15.2% for the quarter and 16.5% for the nine months. Management concluded that disclosure controls and procedures were effective, and no material changes were reported to market risk or risk factors versus the 2022 Form 10-K.

Oct 24, 2023
8-K

Medpace Holdings 8-K Report, Financial Results (Oct 23, 2023)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release on October 23, 2023 reporting results for the three and nine months ended September 30, 2023. Third-quarter revenue was $492.5 million, up 28.3% from $383.7 million a year earlier, with a backlog conversion rate of 19.1%. Net new business awards were $611.5 million, up 29.9%, for a net book-to-bill ratio of 1.24x. GAAP net income was $70.6 million, or $2.22 per diluted share, compared with $66.0 million, or $2.05 per diluted share, in the prior-year quarter. EBITDA was $90.2 million, up 1.0%, with an EBITDA margin of 18.3%, down from 23.3% a year earlier. For the nine months ended September 30, 2023, revenue was $1,387.4 million, up 30.2% on a reported basis, and GAAP net income was $204.5 million, or $6.42 per diluted share. Backlog as of September 30, 2023 was $2,689.5 million, up 20.3%. Cash and cash equivalents were $95.2 million at quarter end, operating cash flow for the third quarter was $114.4 million, and the company paid off its remaining outstanding debt during the quarter. Management guided full-year 2023 revenue to $1.870 billion to $1.890 billion, GAAP net income to $272.0 million to $276.0 million, and diluted EPS to $8.54 to $8.66. For 2024, it forecast revenue of $2.150 billion to $2.200 billion and EBITDA of $390.0 million to $415.0 million. The results were furnished under Item 2.02 and are not deemed filed under Section 18 of the Exchange Act.

Oct 23, 2023
10-Q

Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2023

Medpace Holdings, Inc. reported second-quarter 2023 total revenue, net of $460.9 million, up from $351.2 million in the three months ended June 30, 2022, with net income of $61.1 million versus $49.4 million. For the six months ended June 30, 2023, revenue was $894.9 million and net income was $134.0 million, compared with $682.2 million and $110.7 million a year earlier. Income from operations rose to $164.6 million for the six-month period from $124.4 million. Diluted EPS was $1.93 for the quarter and $4.20 for the six months, compared with $1.46 and $3.16 in the prior-year periods. Net new business awards were $574.8 million for the quarter and $1,130.6 million for the six months, and backlog reached $2,571.9 million as of June 30, 2023, up from $2,168.3 million a year earlier. The filing states that approximately $1,410.0 million to $1,430.0 million of backlog is expected to convert to net revenue over the next twelve months. The company also disclosed approximately $2.9 billion of performance obligations remaining for active projects. On the balance sheet, cash and cash equivalents were $39.1 million and short-term debt was $55.0 million at June 30, 2023. Operating cash flow for the six months was $162.6 million, and the company repurchased $144.0 million of common stock during the period, with $308.8 million of authorization remaining under its new program. The company also amended its credit facility on March 31, 2023, reducing the maximum borrowing to $150.0 million.

Jul 25, 2023
8-K

Medpace Holdings 8-K Report, Financial Results (Jul 24, 2023)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished an Item 2.02 Form 8-K on July 24, 2023, attaching a press release reporting its results for the three and six months ended June 30, 2023. For the second quarter, revenue rose 31.2% to $460.9 million from $351.2 million, and backlog grew 18.6% to $2,571.9 million. Net new business awards were $574.8 million, a 27.6% increase, producing a net book-to-bill ratio of 1.25x. GAAP net income was $61.1 million, or $1.93 per diluted share, compared with $49.4 million, or $1.46 per diluted share, a year earlier. EBITDA rose 22.8% to $83.6 million, with an EBITDA margin of 18.1%. For the first six months of 2023, revenue was $894.9 million and GAAP net income was $134.0 million, or $4.20 per diluted share. Year-to-date EBITDA was $176.5 million, or 19.7% of revenue. The company repurchased 126,281 shares for $23.9 million in the second quarter and had $308.8 million remaining under its share repurchase program at June 30, 2023. Cash and cash equivalents were $39.1 million and short-term debt was $55.0 million at quarter end. For full-year 2023, Medpace forecasts revenue of $1.840 billion to $1.880 billion, GAAP net income of $256.0 million to $271.0 million, EBITDA of $340.0 million to $358.0 million, and diluted EPS of $8.04 to $8.50. The guidance assumes a tax rate of 17.5% to 18.5% and excludes the effect of any share repurchases after June 30, 2023. The press release is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act.

Jul 24, 2023
8-K

Medpace Holdings 8-K Report, Shareholder Vote Results (May 19, 2023)

Medpace Holdings, Inc. held its 2023 Annual Meeting of Stockholders on May 19, 2023. Stockholders elected Brian T. Carley, Femida H. Gwadry-Sridhar, and Robert O. Kraft as Class I Directors, each to serve until the 2026 Annual Meeting. Gwadry-Sridhar received the most support at 27,027,873 votes for and 782,923 withheld. Carley received 15,744,076 votes for and 12,066,720 withheld, and Kraft received 15,166,913 votes for and 12,643,883 withheld. Each director nominee also had 1,172,784 broker non-votes. Stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 28,343,821 for, 630,701 against, and 9,058 abstentions, with no broker non-votes reported. Stockholders also approved, on an advisory basis, the compensation of the Company's Named Executive Officers. The vote was 26,073,214 for, 1,715,903 against, and 21,679 abstentions, with 1,172,784 broker non-votes. The filing reports no other items under Items 5.07(c) or 5.07(d).

May 19, 2023
10-Q

Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2023

Medpace Holdings, Inc. reported first-quarter 2023 revenue, net of $434.1 million, up from $330.9 million in the first quarter of 2022, with net income of $72.9 million compared to $61.3 million a year earlier. Diluted earnings per share were $2.27, versus $1.69. Income from operations was $86.2 million, and the effective income tax rate rose to 15.3% from 6.1%. Growth was primarily driven by Oncology, Metabolic, Cardiology and other therapeutic areas. Total direct costs rose to $303.9 million, including reimbursed out-of-pocket expenses of $152.8 million, which the filing notes can fluctuate significantly from period to period. Net new business awards were $555.8 million for the quarter, compared with $423.0 million a year earlier. Backlog was $2,460.1 million as of March 31, 2023, and the filing states that approximately $1,320.0 million to $1,340.0 million is expected to convert to net revenue over the next twelve months. The company also disclosed approximately $2.9 billion of performance obligations remaining for active projects. Capital allocation was active: the company repurchased 654,787 shares for $120.1 million during the quarter, leaving $332.7 million of authorization under a $500.0 million program approved in the fourth quarter of 2022. Cash rose to $46.9 million, while short-term debt increased to $115.0 million from $50.0 million, and total shareholders' equity fell to $347.3 million from $386.4 million. The company amended its credit facility on March 31, 2023, reducing the borrowing capacity to up to $150.0 million and extending its expiration to March 29, 2024.

Apr 25, 2023
8-K

Medpace Holdings 8-K Report, Financial Results (Apr 24, 2023)

Medpace Holdings, Inc. filed this Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on April 24, 2023, furnishing a press release announcing financial results for the three months ended March 31, 2023. The filing is furnished rather than filed, so it is not subject to Section 18 liability. In the quarter, revenue, net was $434.1 million, up 31.2% from $330.9 million a year earlier, and net new business awards were $555.8 million, up 31.4% from $423.0 million, producing a net book-to-bill ratio of 1.28x. Backlog rose 17.8% to $2,460.1 million as of March 31, 2023. GAAP net income was $72.9 million, or $2.27 per diluted share, compared with $61.3 million, or $1.69 per diluted share, in the prior-year quarter. Net income margin declined to 16.8% from 18.5%, while EBITDA rose 31.9% to $92.8 million, with EBITDA margin of 21.4% versus 21.3% a year earlier. Cash flow from operations was $80.1 million, and the company repurchased 654,787 shares for $120.1 million, leaving $332.7 million under its authorized repurchase program. Short-term debt increased to $115.0 million from $50.0 million at December 31, 2022. For full-year 2023, the company forecast revenue of $1.745 billion to $1.805 billion, GAAP net income of $250.0 million to $269.0 million, EBITDA of $335.0 million to $355.0 million, and diluted EPS of $7.81 to $8.40. Guidance assumes a tax rate of 17.5% to 18.5% and excludes any share repurchases made after March 31, 2023.

Apr 24, 2023
8-K

Medpace Holdings 8-K Report, Material Agreement (Mar 31, 2023)

Medpace Holdings, Inc. (MEDP) reported on a Form 8-K dated March 31, 2023 that it entered into Amendment No. 5 to Loan Documents with PNC Bank, National Association, in connection with its unsecured credit facility. The agreement was executed through its wholly owned subsidiaries, Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor. The amendment changes the aggregate principal amount that may be borrowed under the facility's line of credit to up to $150 million. It also adjusts the interest rate and fee charged on the credit facility and extends the expiration date of the revolving credit note to March 29, 2024. The filing is limited to this material agreement and its related exhibit. The full terms of Amendment No. 5 are filed as Exhibit 10.1, and the filing also includes the Cover Page Interactive Data File embedded within the Inline XBRL document.

Mar 31, 2023
10-K

Medpace Holdings Annual Report, Year Ended Dec 31, 2022

Medpace Holdings, Inc. describes itself as one of the world's leading clinical contract research organizations (CROs) by revenue, solely focused on outsourced clinical development services for the biotechnology, pharmaceutical and medical device industries, with particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI) and Central Nervous System (CNS). For 2022, net revenue rose 27.8% to $1,459,996 thousand ($1.46 billion) from $1,142,377 thousand, and net income increased to $245,368 thousand from $181,848 thousand. Diluted EPS was $7.28 versus $4.81. Backlog grew 17.2% to $2,339.6 million at December 31, 2022, with net new business awards of $1,829.5 million, and approximately $1,200.0 million to $1,220.0 million of backlog is expected to convert to net revenue in 2023. Balance sheet and cash flow shifted notably during the year. Cash and cash equivalents fell to $28.3 million from $461.3 million, largely because of $847.8 million in share repurchases, and short-term debt of $50.0 million was drawn under the revolving Credit Facility, which the filing says is expected to be amended or replaced before its March 31, 2023 expiration. Net cash provided by operating activities was $388.1 million. Total shareholders' equity fell to $386.4 million from $952.9 million, with an accumulated deficit of $359.8 million, reflecting the repurchases. The company had approximately 5,200 employees across 40 countries. The filing highlights several risks for investors: contracts are largely terminable on 30 days' notice, the backlog may not convert at historical rates, most Phase I–IV contracts are fixed-fee, and the Chief Executive Officer and founder, August J. Troendle, controls approximately 23.4% of outstanding shares. Deloitte & Touche LLP issued an unqualified opinion, and management concluded internal control over financial reporting was effective as of December 31, 2022.

Feb 14, 2023
8-K

Medpace Holdings 8-K Report, Financial Results (Feb 13, 2023)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished an 8-K under Item 2.02 on February 13, 2023, announcing its financial results for the three and twelve months ended December 31, 2022. Fourth-quarter 2022 revenue rose 27.7% to $394.1 million from $308.6 million, and net new business awards were $485.1 million, for a net book-to-bill ratio of 1.23x. GAAP net income was $68.7 million, or $2.12 per diluted share, versus $50.0 million, or $1.32 per diluted share, a year earlier. EBITDA increased 30.9% to $80.4 million, a 20.4% margin. For full year 2022, revenue increased 27.8% to $1,460.0 million and GAAP net income was $245.4 million, or $7.28 per diluted share. Full-year EBITDA rose 38.1% to $308.1 million, or 21.1% of revenue. Backlog as of December 31, 2022 increased 17.2% to $2,339.6 million. The company repurchased approximately 5.7 million shares for $847.7 million during 2022 and had $452.8 million remaining under its share repurchase program. Cash and cash equivalents were $28.3 million at year-end, down from $461.3 million, and short-term debt was $50.0 million. For 2023, Medpace guided to revenue of $1.690 billion to $1.750 billion, GAAP net income of $245.0 million to $265.0 million, EBITDA of $325.0 million to $350.0 million, and diluted GAAP EPS of $7.53 to $8.14, assuming a 17.5% to 18.5% tax rate and no future share repurchases after December 31, 2022. The accompanying press release is furnished, not filed, under Item 2.02.

Feb 13, 2023
8-K

Medpace Holdings 8-K Report, Executive Changes (Jan 18, 2023)

Medpace Holdings, Inc. filed this Form 8-K under Item 5.02 to report that its Board of Directors, on January 16, 2023, unanimously approved the election of Dr. Femida H. Gwadry-Sridhar to fill the Class I director vacancy, effective that same day. Following a recommendation from the independent directors, she will serve as a Class I director until the 2023 Annual Meeting of Stockholders, and she is expected to be appointed to the Nominating and Governance Committee. Dr. Gwadry-Sridhar is the Founder and Chief Executive Officer of Pulse Infoframe Inc., a privately held real-world evidence generation platform company she has led since 2011. The filing describes her academic background, including appointments at Western University and as a visiting professor at the University of Southern California, along with more than 220 publications and recognition as a career scientist and lifetime fellow of the Canadian Institute of Health Research. Under the Company's standard non-employee director compensation program, she received on January 16, 2023 an option to purchase 573 shares of common stock at an exercise price equal to the January 13, 2023 closing price, the last trading day before her election date. The option has a seven-year term, and the Company has entered into its standard director and officer indemnification agreement with her.

Jan 18, 2023
8-K

Medpace Holdings 8-K Report, Executive Changes (Jan 3, 2023)

Medpace Holdings, Inc. filed this Current Report on Form 8-K with a date of report of December 31, 2022, disclosing a single board change under Item 5.02. Thomas C. King notified the company on December 31, 2022 of his resignation from its Board of Directors, effective that same day. The filing states that his resignation did not result from any disagreement with the company on any matter relating to its operations, policies or practices. The report was signed by Stephen P. Ewald, General Counsel and Corporate Secretary, on January 3, 2023. The filing contains no financial results, guidance, or operational metrics. Its significance for investors is limited to governance: a director departure effective at year-end, with no stated disagreement behind it. The filing does not state a replacement director or any change to board committee composition. The registrant is listed on the Nasdaq Global Select Market under the symbol MEDP, and its principal executive offices are in Cincinnati, Ohio.

Jan 3, 2023
10-Q

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2022

Medpace Holdings, Inc. reported strong top-line growth in the third quarter of 2022. Net revenue was $383.7 million for the three months ended September 30, 2022, up $88.2 million, or 29.8%, from $295.6 million a year earlier. For the nine months, net revenue was $1,065.9 million, up 27.8% from $833.8 million. Net income rose to $66.0 million for the quarter (diluted EPS of $2.05, versus $1.29) and to $176.7 million for the nine months (diluted EPS of $5.18, versus $3.49). The filing attributes revenue growth primarily to Oncology, Metabolic, Cardiology and Central Nervous System therapeutic areas. Backlog increased 20.9% to $2,236.2 million as of September 30, 2022, and net new business awards were $470.9 million for the quarter and $1,344.4 million for the nine months. Capital allocation dominated the balance sheet. During the nine months, the company repurchased 5,463,244 shares for $800.5 million and has now completed all authorized repurchases under its program. Cash and cash equivalents fell to $31.0 million from $461.3 million at December 31, 2021, and the company drew $139.7 million on its revolving credit facility, which is classified as short-term debt. Total shareholders' equity declined to $349.9 million from $952.9 million, and the company reported an accumulated deficit of $(380.1) million compared with retained earnings of $235.0 million at year-end 2021. Operating cash flow was $251.4 million for the nine months, and $110.1 million was available for borrowing under the credit facility. The filing also highlights new risk factor language on operating margins, which could decrease due to competitive or inflationary pricing pressure. It adds risk factor discussion on international operations, including the conflict involving Russia and Ukraine, and notes that the COVID-19 pandemic continues to disrupt clinical sites and trial enrollment. Management stated that the future financial impact of the pandemic cannot be reasonably estimated. Total performance obligations remaining for active projects were approximately $2.5 billion as of September 30, 2022.

Oct 25, 2022
8-K

Medpace Holdings 8-K Report, Financial Results (Oct 24, 2022)

Medpace Holdings, Inc. reported financial results for the third quarter and nine months ended September 30, 2022, in a press release furnished as Exhibit 99.1. Third-quarter revenue rose 29.8% to $383.7 million from $295.6 million, and GAAP net income was $66.0 million, or $2.05 per diluted share, versus $48.6 million, or $1.29 per diluted share, a year earlier. EBITDA increased 48.5% to $89.3 million, with an EBITDA margin of 23.3%. Backlog grew 20.9% to $2.2 billion, and net new business awards were $470.9 million, a net book-to-bill ratio of 1.23x. For the nine months, revenue was $1,065.9 million, up 27.8% on a reported basis, and GAAP net income was $176.7 million, or $5.18 per diluted share. The company repurchased $800.7 million of common stock in the first nine months, and its cash and cash equivalents fell to $31.0 million at September 30, 2022, from $461.3 million at December 31, 2021. Short-term debt was $139.7 million. On October 21, 2022, the Board authorized share repurchases of up to $500 million. The company raised no new guidance beyond the figures given. For full-year 2022, it forecasts revenue of $1.440 billion to $1.460 billion, GAAP net income of $232.0 million to $236.0 million, and diluted EPS of $6.88 to $7.00. For 2023, it forecasts revenue of $1.680 billion to $1.740 billion and EBITDA of $325.0 million to $350.0 million.

Oct 24, 2022
10-Q

Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2022

Medpace Holdings, Inc. reported strong second-quarter 2022 results, with revenue of $351.2 million for the three months ended June 30, 2022, up from $278.3 million a year earlier, and net income of $49.4 million versus $39.9 million. For the six months, revenue was $682.2 million and net income was $110.7 million, with diluted earnings per share of $3.16 compared with $2.20. The filing states that the increase was primarily driven by growth in the Oncology, Metabolic, Cardiology and Central Nervous System therapeutic areas. Net new business awards were $450.6 million for the quarter and $873.6 million for the six months, and backlog reached $2,168.3 million as of June 30, 2022. The balance sheet shifted sharply during the first half of 2022. Cash and cash equivalents fell to $42.6 million from $461.3 million at December 31, 2021, primarily because of share repurchases. The company bought back $800.5 million of stock in the first six months, and it completed all authorized repurchases under its program as of June 30, 2022. Shareholders' equity declined to $283.3 million from $952.9 million, and the accumulated deficit reached $446.1 million, reflecting retirement of repurchased shares in excess of par value. To fund the buybacks, the company drew $299.2 million on its revolving credit facility, leaving $249.7 million of short-term debt outstanding, which is due in 2023. The Credit Facility's capacity was increased to $250.0 million, and the filing states that only $0.1 million was available for borrowing as of June 30, 2022. Operating cash flow was $142.9 million for the six months, up from $120.1 million. Management attributed the rise in direct costs mainly to higher reimbursed out-of-pocket expenses and personnel costs. The filing also flags that COVID-19 and the conflict involving Russia and Ukraine remain sources of uncertainty, and it adds a risk factor on operating margin pressure from competitive pricing and inflation.

Jul 26, 2022
8-K

Medpace Holdings 8-K Report, Financial Results (Jul 25, 2022)

Medpace Holdings, Inc. reported second quarter 2022 results in a press release furnished under Item 2.02 of this Form 8-K. Revenue rose 26.2% to $351.2 million from $278.3 million in the prior-year quarter, and on a constant currency organic basis revenue increased 27.7%. Net new business awards were $450.6 million, up 16.3% from $387.6 million, for a net book-to-bill ratio of 1.28x. Backlog grew 24.4% to $2.2 billion as of June 30, 2022. GAAP net income was $49.4 million, or $1.46 per diluted share, compared with $39.9 million, or $1.06 per diluted share, a year earlier. EBITDA increased 42.0% to $68.1 million, a 19.4% margin, versus $47.9 million in the prior-year quarter. The company also reported a sharp change in its balance sheet during the quarter. Cash and cash equivalents were $42.6 million at June 30, 2022, compared with $461.3 million at December 31, 2021. Short-term debt was $249.7 million. Medpace repurchased approximately 2.7 million shares at an average price of $137.86 per share, totaling $374.6 million in the second quarter, and stated that it has completed all authorized share repurchases under its repurchase program. Operating cash flow in the second quarter was $96.6 million. For full-year 2022, Medpace forecast revenue of $1.405 billion to $1.435 billion, representing growth of 23.0% to 25.6% over 2021 revenue of $1.142 billion, GAAP net income of $205.0 million to $215.0 million, and EBITDA of $268.0 million to $280.0 million. Diluted EPS is forecast at $6.07 to $6.36, based on 33.8 million diluted weighted-average shares and a tax rate of 14.5% to 15.5%. The guidance does not reflect any share repurchases after June 30, 2022. The company expects a foreign exchange revenue headwind of approximately $4.0 million and an EBITDA tailwind of approximately $3.0 million.

Jul 25, 2022
8-K

Medpace Holdings 8-K Report, Corporate Update (Jun 10, 2022)

Medpace Holdings, Inc. filed this Form 8-K on June 10, 2022 under Item 8.01 (Other Events) to disclose a change to its share repurchase program. As of June 10, 2022, the Board of Directors approved an increase of $50 million to the Company's existing stock repurchase program. The filing states that the timing, price and volume of repurchases will depend on market conditions, applicable securities laws and other factors. Repurchases may be made from time to time through solicited or unsolicited open-market transactions, privately negotiated transactions, or pursuant to a Rule 10b5-1 plan. The filing also notes that the program may be discontinued or amended at any time without notice. The filing does not state the program's remaining authorization or any repurchases made to date.

Jun 10, 2022
8-K

Medpace Holdings 8-K Report, Corporate Update (May 26, 2022)

Medpace Holdings, Inc. (MEDP) filed a Form 8-K on May 26, 2022 under Item 8.01 (Other Events) to disclose two capital allocation updates. As of May 25, 2022, the Board of Directors approved a $60 million increase to the Company's stock repurchase program. The filing states that repurchases will depend on market conditions, securities laws and other factors, may be made in the open market, in privately negotiated transactions, or under a Rule 10b5-1 plan, and that the program may be discontinued or amended at any time without notice. The filing also reports repurchase activity since April 22, 2022. Between that date and May 25, 2022, the Company repurchased 1,597,007 shares of common stock for treasury, which the filing says resulted in a decrease of approximately 5% of outstanding shares measured from April 22, 2022. As of May 25, 2022, the Company had 32,065,701 shares of common stock outstanding. For investors, the key takeaways are the expanded buyback authorization and the recent pace of share retirement through treasury purchases, which reduces the share count. The filing contains no financial results, guidance, or operational updates.

May 26, 2022
8-K

Medpace Holdings 8-K Report, Shareholder Vote Results (May 20, 2022)

On May 20, 2022, Medpace Holdings, Inc. held its 2022 Annual Meeting of Stockholders. Stockholders elected two Class III directors, August J. Troendle and Ashley M. Keating, to serve until the 2025 Annual Meeting. Troendle received 23,374,363 votes for and 7,211,789 withheld. Keating received 12,863,441 votes for and 17,722,711 withheld, so more shares were withheld than voted for him. The filing reports that both nominees were elected. Stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 30,576,845 votes for, 676,331 against, and 13,308 abstaining. In a non-binding advisory vote, stockholders approved the compensation of the Company's Named Executive Officers, with 22,093,994 votes for, 8,458,621 against, and 33,537 abstaining. The filing lists 680,332 broker non-votes on the director and say-on-pay proposals. The filing reports no other matters submitted to a vote. Its key investor takeaways are the board election, the auditor ratification, and the say-on-pay approval, with the notably high withheld count for Keating as the main point to watch.

May 20, 2022